John S Bomalaski Selected Research

ADI PEG20

1/2022	A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
12/2021	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
1/2021	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
1/2021	Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
11/2020	Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
12/2019	Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
1/2019	A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
1/2019	MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
9/2018	Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
12/2017	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John S Bomalaski Research Topics

Disease

24	Neoplasms (Cancer) 01/2021 - 04/2002
10	Melanoma (Melanoma, Malignant) 05/2022 - 04/2002
6	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 04/2002
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 06/2015
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2020 - 08/2015
3	Citrullinemia 12/2017 - 02/2004
2	Uveal melanoma 05/2022 - 01/2022
2	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2015
2	Inflammation (Inflammations) 01/2022 - 12/2006
2	Hepatitis C 12/2021 - 01/2007
2	Carcinoma (Carcinomatosis) 09/2018 - 01/2015
2	Neuroendocrine Carcinoma 09/2018 - 08/2015
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 02/2014
2	Hyperuricemia 06/2004 - 09/2002
2	Gout 06/2004 - 09/2002
2	Liver Neoplasms (Liver Cancer) 05/2004 - 09/2003
1	Insulin Resistance 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Viremia 12/2021
1	Starvation 12/2021
1	Disease Progression 12/2021
1	Hepatitis B 12/2021
1	Fibrosis (Cirrhosis) 12/2021
1	Hypersensitivity (Allergy) 01/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2019
1	Glioma (Gliomas) 01/2019
1	Adenocarcinoma 12/2017
1	Malignant Mesothelioma 01/2017
1	Mesothelioma 01/2017
1	Neutropenia 01/2017
1	Fatigue 01/2017
1	Lung Neoplasms (Lung Cancer) 08/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2015
1	Ovarian Epithelial Carcinoma 01/2015
1	Ovarian Neoplasms (Ovarian Cancer) 01/2015
1	Virus Diseases (Viral Diseases) 01/2007
1	Chronic Hepatitis C 01/2007
1	Pneumonia (Pneumonitis) 12/2006

Drug/Important Bio-Agent (IBA)

27	Arginine (L-Arginine)FDA Link 05/2022 - 04/2002
22	ADI PEG20IBA 01/2022 - 10/2002
14	arginine deiminaseIBA 01/2022 - 04/2002
14	EnzymesIBA 09/2018 - 04/2002
12	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 01/2021 - 10/2002
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2007 - 10/2002
4	methoxypolyethylene glycol succinimidylsuccinateIBA 01/2007 - 10/2002
3	Amino Acids FDA Link 12/2019 - 10/2005
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2013 - 05/2002
2	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2019
2	Pemetrexed (MTA)FDA Link 01/2022 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 02/2014
2	Monoclonal AntibodiesIBA 08/2015 - 02/2004
2	Messenger RNA (mRNA)IBA 01/2015 - 10/2002
2	Essential Amino AcidsIBA 10/2005 - 10/2002
2	Urate Oxidase (Uricase)IBA 06/2004 - 09/2002
2	Uric Acid (Urate)IBA 06/2004 - 09/2002
1	IpilimumabIBA 05/2022
1	NivolumabIBA 05/2022
1	Immune Checkpoint InhibitorsIBA 05/2022
1	Virulence Factors (Pathogenicity Factors)IBA 01/2022
1	Thymidylate SynthaseIBA 12/2021
1	MicronutrientsIBA 12/2021
1	Fluorouracil (Carac)FDA LinkGeneric 12/2021
1	Leucovorin (Folinic Acid)FDA Link 12/2021
1	DNA (Deoxyribonucleic Acid)IBA 12/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021
1	pembrolizumabIBA 01/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2019
1	Bevacizumab (Avastin)FDA Link 01/2019
1	130-nm albumin-bound paclitaxelIBA 12/2017
1	Gemcitabine FDA Link 12/2017
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 01/2017
1	Peptide Initiation Factors (Initiation Factor)IBA 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	ParaffinIBA 08/2015
1	Formaldehyde (Formol)FDA Link 08/2015
1	Docetaxel (Taxotere)FDA Link 06/2015
1	taxaneIBA 01/2015
1	PlatinumIBA 01/2015
1	Proteins (Proteins, Gene)FDA Link 01/2015
1	Urea (Carbamide)FDA LinkGeneric 02/2014
1	Folic Acid AntagonistsIBA 02/2014
1	thymidine kinase 1IBA 12/2013
1	ThymidineIBA 12/2013
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2012
1	Prostaglandins EIBA 12/2006
1	Losartan (Cozaar)FDA LinkGeneric 06/2004
1	Allopurinol (Remid)FDA LinkGeneric 06/2004
1	Amlodipine (Norvasc)FDA LinkGeneric 06/2004
1	Biological ProductsIBA 09/2003
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 09/2003
1	CitrullineIBA 09/2003
1	Ligases (Synthetase)IBA 09/2003
1	Pharmaceutical PreparationsIBA 09/2003
1	Argininosuccinate LyaseIBA 10/2002

Therapy/Procedure

14	Therapeutics 12/2021 - 02/2004
2	Drug Therapy (Chemotherapy) 01/2019 - 01/2015
1	Immunotherapy 01/2022
1	Radiotherapy 12/2019
1	Enzyme Therapy 02/2004